Teledermatology and Modulation of Antibiotic Dose in Acne Vulgaris
NCT ID: NCT02905851
Last Updated: 2018-07-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
4 participants
INTERVENTIONAL
2016-05-31
2018-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Photodynamic Therapy of Acne Vulgaris - a Randomized Blinded Controlled Study
NCT00206895
Evaluation of the Role of Propionibacterium Acnes in the Inflammatory Lesions Associated With Acne Vulgaris
NCT01929057
Subantimicrobial Doxycycline in Acne
NCT05399290
Comparison Between Interactive Internet-based Education and Counseling for the Management of Acne With That of Internet-based Education Alone
NCT02031718
Anti-microbial Role of Non-antibiotic Agents Against Cutibacterium Acnes in Patients With Acne Vulgaris
NCT06179056
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
There are two arms of the study:
1. Feedback group
2. Non feedback group
All subjects will be randomised to either group, all subjects will take photos of their face and answer questions at baseline, visit 2 (1 month), visit 3 (2 months), visit 4 (3 months).
The investigators will then use measurements of acne grading (patient grading, investigator global assessment, lesion counting, global acne grading) to reduce/taper antibiotics in the feedback group.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Non Feedback
No feedback given to this group regarding their antibiotic use Subjects take images and answer questions during the study like the feedback group, but in this group no feedback re dosing is given.
Non Feedback group
To use as control to see if antibiotic burden has been reduced in the active feedback group
Feedback group
Feedback given to this group regarding their antibiotic use after baseline.
If the subject is in the feedback group, after this visit, a dermatologist will review all images and the survey results and give the patient information about whether they should:
1. Continue current dose
2. Reduce dose if there is at least a one point improvement in both the investigator acne global assessment AND the patient acne global assessment scores: A dose reduction will be such that the dose is halved from the previous dose. For example if the subject is on minocycline or doxycycline 100 mg twice daily, they will be reduced to minocycline or doxycycline 100 mg daily.
3. Increase dose if had been previously reduced, dose will not be increased beyond the initial starting dose.
Feedback group
Monitoring ability to use teledermatology to modify antibiotic burden
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Feedback group
Monitoring ability to use teledermatology to modify antibiotic burden
Non Feedback group
To use as control to see if antibiotic burden has been reduced in the active feedback group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects who have been prescribed doxycycline or minocycline by their physician for acne vulgaris but have not initiated treatment yet.
Exclusion Criteria
* Those who have used oral antibiotics within the last 4 weeks
* Those who have been initiated or changed brand of oral contraceptive pill within the last one month.
* Those subjects who cannot engage with the teledermatology platform
* Prisoners
* Adults unable to consent
15 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of California, Davis
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Raja Sivamani, MD
Role: PRINCIPAL_INVESTIGATOR
UC Davis
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UC Davis Department of Dermatology, Clinical Trials Unit
Sacramento, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
869597
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.